New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07477912
Summary
This study is testing a new type of treatment called anti-BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or stopped responding to other treatments. Doctors will take a patient's own immune cells, modify them in a lab to better fight the cancer, and then infuse them back. The main goals are to see if this treatment is safe and if it can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology
RECRUITINGMinsk, 220087, Belarus
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.